Objective. To assess the possibility of intralesional therapy for the treatment of Peyronie's disease, we have verified the safety and tolerability of intralesional injections of Iloprost ( an I 2 Prostacyclin analogue) for its property to suppress the production of CTFG in fibroblasts. CTFG is a connective tissue growth factor that acts in concert with TGF-β to stimulate the fibrotic process. Materials and methods. 38 patients with Peyronie’s disease were preliminarily evaluated by considering the symptoms, the degree of penile curvature, and the size of the plaque. Each patient received weekly intralesional injections of 200 ng of Iloprost in 1 ml normal saline for 5 weeks. If tolerated, the single dose was increased weekly to the maximum of 400 ng (2ml). All patients tolerated well a Iloprost dose of 200 ng; 19 of them reached a 300 ng dose and 14 tolerated a 400 ng dose without showing side effects. There was no placebo control group in this phase I study. Results. To evaluate the efficacy of the treatment, all the patients were preliminarily evaluated by an at-home photography. Two months after the end of the treatment they were re-evaluated. Almost all patients showed mild side effects (burning or pain) during the treatment at the site of injection. 29% of the patients showed an improvement in curvature. Conclusion. According to the results, therapy with intralesional Iloprost (prostacyclin drug with antifibrotic properties) in Peyronie’s disease seems to be an encouraging alternative to surgery.

Pavone, C., Napoli, G., Caruana, G., Alonge, V., Usala, M., Abbadessa, D. (2011). SAFETY AND TOLERABILITY OF LOCAL TREATMENT WITH ILOPROST, A PROSTACYCLIN ANALOGUE, IN PATIENTS WITH PEYRONIE'S DISEASE. A PHASE I STUDY. BJU INTERNATIONAL, 110(1), 117-121 [10.1111/j.1464-410X.2011.10733.x].

SAFETY AND TOLERABILITY OF LOCAL TREATMENT WITH ILOPROST, A PROSTACYCLIN ANALOGUE, IN PATIENTS WITH PEYRONIE'S DISEASE. A PHASE I STUDY

PAVONE, Carlo;ABBADESSA, Daniela
2011-01-01

Abstract

Objective. To assess the possibility of intralesional therapy for the treatment of Peyronie's disease, we have verified the safety and tolerability of intralesional injections of Iloprost ( an I 2 Prostacyclin analogue) for its property to suppress the production of CTFG in fibroblasts. CTFG is a connective tissue growth factor that acts in concert with TGF-β to stimulate the fibrotic process. Materials and methods. 38 patients with Peyronie’s disease were preliminarily evaluated by considering the symptoms, the degree of penile curvature, and the size of the plaque. Each patient received weekly intralesional injections of 200 ng of Iloprost in 1 ml normal saline for 5 weeks. If tolerated, the single dose was increased weekly to the maximum of 400 ng (2ml). All patients tolerated well a Iloprost dose of 200 ng; 19 of them reached a 300 ng dose and 14 tolerated a 400 ng dose without showing side effects. There was no placebo control group in this phase I study. Results. To evaluate the efficacy of the treatment, all the patients were preliminarily evaluated by an at-home photography. Two months after the end of the treatment they were re-evaluated. Almost all patients showed mild side effects (burning or pain) during the treatment at the site of injection. 29% of the patients showed an improvement in curvature. Conclusion. According to the results, therapy with intralesional Iloprost (prostacyclin drug with antifibrotic properties) in Peyronie’s disease seems to be an encouraging alternative to surgery.
2011
Settore MED/24 - Urologia
Pavone, C., Napoli, G., Caruana, G., Alonge, V., Usala, M., Abbadessa, D. (2011). SAFETY AND TOLERABILITY OF LOCAL TREATMENT WITH ILOPROST, A PROSTACYCLIN ANALOGUE, IN PATIENTS WITH PEYRONIE'S DISEASE. A PHASE I STUDY. BJU INTERNATIONAL, 110(1), 117-121 [10.1111/j.1464-410X.2011.10733.x].
File in questo prodotto:
File Dimensione Formato  
j.1464-410X.2011.10733.x.pdf

Solo gestori archvio

Descrizione: ARTICOLO IN EXTENSO
Dimensione 280.3 kB
Formato Adobe PDF
280.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/78956
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact